Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from helios

10.1111/ajt.15985

http://scihub22266oqcxt.onion/10.1111/ajt.15985
suck pdf from google scholar
32359210!7267667!32359210
unlimited free pdf from europmc32359210    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32359210  :  Publisher
PDF vom PMID32359210

suck abstract from ncbi

pmid32359210
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report #MMPMID32359210
  • Hammami MB; Garibaldi B; Shah P; Liu G; Jain T; Chen PH; Kim AK; Avdic E; Petty B; Strout S; Fine DM; Niranjan-Azadi A; Garneau WM; Cameron AM; Monroy Trujillo JM; Gurakar A; Avery R
  • Am J Transplant 2020[Aug]; 20 (8): 2254-2259 PMID32359210show ga
  • The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease. There are limited published data on the epidemiology and outcomes of COVID-19 infection among organ transplant recipients. After initial flulike symptoms, progression to an inflammatory phase may occur, characterized by cytokine release rapidly leading to respiratory and multiorgan failure. We report the clinical course and management of a liver transplant recipient on hemodialysis, who presented with COVID-19 pneumonia, and despite completing a 5-day course of hydroxychloroquine, later developed marked inflammatory manifestations with rapid improvement after administration of off-label, single-dose tocilizumab. We also highlight the role of lung ultrasonography in early diagnosis of the inflammatory phase of COVID-19. Future investigation of the effects of immunomodulators among transplant recipients with COVID-19 infection will be important.
  • |*Liver Transplantation[MESH]
  • |*Renal Dialysis[MESH]
  • |*Transplant Recipients[MESH]
  • |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH]
  • |COVID-19[MESH]
  • |Carcinoma, Hepatocellular/complications/surgery[MESH]
  • |Coronavirus Infections/*complications/drug therapy[MESH]
  • |Hepatitis C/complications/surgery[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/therapeutic use[MESH]
  • |Inflammation[MESH]
  • |Liver Cirrhosis/complications/surgery[MESH]
  • |Liver Neoplasms/complications/surgery[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*complications/drug therapy[MESH]
  • |Reoperation[MESH]
  • |Treatment Outcome[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    2254 8.20 2020